Wall Street analysts expect that DaVita HealthCare Partners Inc. (NYSE:DVA) will announce earnings of $0.90 per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for DaVita HealthCare Partners’ earnings. The highest EPS estimate is $0.94 and the lowest is $0.87. DaVita HealthCare Partners reported earnings of $1.01 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 10.9%. The company is scheduled to issue its next earnings results after the market closes on Tuesday, August 1st.
On average, analysts expect that DaVita HealthCare Partners will report full year earnings of $3.49 per share for the current fiscal year, with EPS estimates ranging from $3.34 to $3.57. For the next financial year, analysts expect that the firm will report earnings of $3.81 per share, with EPS estimates ranging from $3.53 to $4.14. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for DaVita HealthCare Partners.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.82 by $0.03. The firm had revenue of $3.70 billion for the quarter, compared to analysts’ expectations of $3.69 billion. DaVita HealthCare Partners had a return on equity of 14.85% and a net margin of 8.28%.
A number of equities research analysts have recently issued reports on DVA shares. TheStreet upgraded shares of DaVita HealthCare Partners from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Zacks Investment Research upgraded shares of DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $77.00 target price on the stock in a research note on Tuesday, April 18th. Jefferies Group LLC set a $70.00 target price on shares of DaVita HealthCare Partners and gave the company a “buy” rating in a research note on Friday, May 26th. BidaskClub lowered shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research note on Saturday, July 8th. Finally, Goldman Sachs Group, Inc. (The) restated a “sell” rating and issued a $62.00 target price on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $69.50.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 1.54% during trading on Monday, hitting $66.42. The company’s stock had a trading volume of 1,351,677 shares. DaVita HealthCare Partners has a 52 week low of $54.50 and a 52 week high of $78.40. The firm’s 50 day moving average price is $64.82 and its 200-day moving average price is $66.02. The company has a market cap of $12.93 billion, a PE ratio of 10.91 and a beta of 0.89.
In related news, CEO Javier Rodriguez sold 1,294 shares of the business’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $66.21, for a total transaction of $85,675.74. Following the completion of the sale, the chief executive officer now owns 99,111 shares of the company’s stock, valued at approximately $6,562,139.31. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William L. Roper sold 12,994 shares of the business’s stock in a transaction dated Thursday, May 4th. The shares were sold at an average price of $65.89, for a total transaction of $856,174.66. Following the sale, the director now directly owns 45,277 shares of the company’s stock, valued at approximately $2,983,301.53. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,702 shares of company stock valued at $1,495,492. Insiders own 2.10% of the company’s stock.
Several large investors have recently made changes to their positions in DVA. Becker Capital Management Inc. increased its stake in shares of DaVita HealthCare Partners by 22.7% in the fourth quarter. Becker Capital Management Inc. now owns 681,865 shares of the company’s stock worth $43,776,000 after buying an additional 126,205 shares in the last quarter. Kentucky Retirement Systems purchased a new position in DaVita HealthCare Partners during the fourth quarter valued at approximately $736,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new position in DaVita HealthCare Partners during the fourth quarter valued at approximately $328,000. Macquarie Group Ltd. boosted its position in DaVita HealthCare Partners by 31.5% in the fourth quarter. Macquarie Group Ltd. now owns 84,700 shares of the company’s stock valued at $5,438,000 after buying an additional 20,300 shares during the period. Finally, Norman Fields Gottscho Capital Management LLC boosted its position in DaVita HealthCare Partners by 8.4% in the first quarter. Norman Fields Gottscho Capital Management LLC now owns 87,713 shares of the company’s stock valued at $5,962,000 after buying an additional 6,765 shares during the period. 81.93% of the stock is owned by institutional investors and hedge funds.
DaVita HealthCare Partners Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Get a free copy of the Zacks research report on DaVita HealthCare Partners (DVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
